BioMarin Pharmaceutical Inc
In the published model solve dated 2026-Q2, anchored at $61.89, BioMarin Pharmaceutical Inc (BMRN) is priced for +24.4% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• BioMarin sells into disease populations so small that, apart from PALYNZIQ and KUVAN, the annual filing states its therapies ⟦"have no direct approved competition currently on the market in the U.S. or the EU"⟧, though rivals are in development. • Concentration is the flip side of that position: VOXZOGO alone is 29% of revenue, and the company's most recent attempt to add a fourth growth leg ended with ROCTAVIAN pulled from the market by management decision in December 2025. • The next schedul
Is BMRN overvalued? See what's priced in →
535 institutional managers reported holding BMRN in 13F filings for the quarter ended 2026-03-31. Together they hold about 93% of the company; the top 10 hold 51%. 73 opened new positions that quarter. Held by BlackRock, Vanguard Group, Dodge & Cox, among others. On the short side, 12.5M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (6.1 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BMRN's share count grew 5.3% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at BMRN over the trailing three years. Absence is a fact about the company, not a signal. 19 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BMRN's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-03 | +1.6% | -0.5% |
| 2023-11-03 | -2.2% | +21.2% |
| 2024-02-27 | +3.0% | -10.9% |
| 2024-04-27 | -10.7% | +1.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BMRN's latest 8-K filings: 2026-06-04 (items 5.02, 5.07); 2026-05-04 (items 2.02, 9.01); 2026-04-27 (items 1.01, 2.01, 2.03, 7.01, 9.01); 2026-04-23 (items 8.01); 2026-03-16 (items 8.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.